Canopus Biopharma Incorporated Stock Gross Profit
| CBIA Stock | USD 0.0001 0.00 0.00% |
Canopus BioPharma Incorporated fundamentals help investors to digest information that contributes to Canopus BioPharma's financial success or failures. It also enables traders to predict the movement of Canopus Pink Sheet. The fundamental analysis module provides a way to measure Canopus BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Canopus BioPharma pink sheet.
Canopus |
Canopus BioPharma Incorporated Company Gross Profit Analysis
Canopus BioPharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Canopus BioPharma Incorporated reported 0.0 of gross profit. This is 100.0% lower than that of the Financial Services sector and about the same as Shell Companies (which currently averages 0.0) industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Canopus Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Canopus BioPharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Canopus BioPharma could also be used in its relative valuation, which is a method of valuing Canopus BioPharma by comparing valuation metrics of similar companies.Canopus BioPharma is currently under evaluation in gross profit category among its peers.
Canopus Fundamentals
| Shares Outstanding | 9.3 M | |||
| Net Income | 1.68 M | |||
| Cash Flow From Operations | 1.98 M | |||
| Beta | -2.23 | |||
| Market Capitalization | 364.56 K | |||
| Total Asset | 1.56 M | |||
| Retained Earnings | (10.29 M) | |||
| Current Asset | 92 K | |||
| Current Liabilities | 2.36 M | |||
| Z Score | -8.4 | |||
| Net Asset | 1.56 M |
About Canopus BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Canopus BioPharma Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Canopus BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Canopus BioPharma Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Canopus Pink Sheet
Canopus BioPharma financial ratios help investors to determine whether Canopus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canopus with respect to the benefits of owning Canopus BioPharma security.